Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Modera...

por Prasenohadi, Prasenohadi, Burhan, Erlina, Dhunny, Sri, Suharno, Wahyuningsih, Wabnitz, Paul, Kim, Yoon-Won, Petrosillo, Nicola
Publicado 2022

Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial

por Maurer, Marcus, Saini, Sarbjit S., McLendon, Kristi, Wabnitz, Paul, Kim, Sunghyun, Ahn, Keumyoung, Kim, Suyoung, Lee, Sewon, Grattan, Clive
Publicado 2022